Emerging Treatments for Myelofibrosis


Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.

Related Videos
Naseema Gangat, MBBS
Ashwin Kishtagari, MD
Somedeb Ball, MBBS
Lori A. Leslie, MD
Changchun Deng, MD, PhD
Rebecca Klisovic, MD
Guenther Koehne, MD, PhD
Sunil Iyer, MD
Ibrahim Aldoss, MD
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University